SCHEDULE: BlackRock Discloses 5.5% Stake in Vanda Pharmaceuticals
Beneficial Ownership Report (Schedule 13G Amendment)
BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 5.5% beneficial ownership stake in Vanda Pharmaceuticals Inc. common stock.
Summary
- BlackRock Portfolio Management LLC reported beneficial ownership of 3,251,563 shares of Vanda Pharmaceuticals Inc. common stock.
- This ownership represents 5.5% of the total outstanding shares of Vanda Pharmaceuticals Inc.'s common stock.
- BlackRock Portfolio Management LLC holds sole voting power over 2,796,972 shares and sole dispositive power over 3,251,563 shares.
- The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Vanda Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership without specific positive or negative operational or financial news for the issuer.
Positives
- A significant 5.5% stake held by a major institutional investor like BlackRock Portfolio Management LLC may be viewed as a vote of confidence in Vanda Pharmaceuticals Inc.
Risks
- No specific company-related risks are disclosed in this beneficial ownership report.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Vanda Pharmaceuticals Inc.'s future performance or BlackRock's investment strategy beyond the ordinary course of business.
Industry Context
The disclosure of a significant stake by a major asset manager like BlackRock in a pharmaceutical company like Vanda Pharmaceuticals Inc. is a routine event in the investment landscape, reflecting institutional portfolio allocation decisions within the healthcare and biotechnology sectors.
Stakeholder Impact
- Shareholders of Vanda Pharmaceuticals Inc. gain transparency regarding a significant institutional holder, which can influence market perception and liquidity.
- BlackRock's clients benefit from the disclosure of their investment in Vanda Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-07-01 | Effective date of the Power of Attorney granted by BlackRock Portfolio Management LLC. |
| 2025-12-31 | Date of the event which requires the filing of this statement (beneficial ownership threshold met/changed). |
| 2026-01-21 | Date of signature for the Schedule 13G filing. |
Keywords
Vanda Pharmaceuticals, BlackRock, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.